Tokio Marine Asset Management Co. Ltd. Has $4.85 Million Position in Bristol-Myers Squibb Company (BMY)
Tokio Marine Asset Management Co. Ltd. decreased its position in Bristol-Myers Squibb Company (NYSE:BMY) by 34.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 87,076 shares of the biopharmaceutical company’s stock after selling 45,566 shares during the quarter. Tokio Marine Asset Management Co. Ltd.’s holdings in Bristol-Myers Squibb were worth $4,852,000 at the end of the most recent quarter.
A number of other large investors have also recently modified their holdings of the stock. Waldron LP acquired a new stake in Bristol-Myers Squibb during the first quarter worth approximately $475,000. Westbourne Investment Advisors Inc. raised its holdings in Bristol-Myers Squibb by 16.8% during the first quarter. Westbourne Investment Advisors Inc. now owns 50,625 shares of the biopharmaceutical company’s stock worth $2,753,000 after purchasing an additional 7,290 shares in the last quarter. Fisher Asset Management LLC raised its holdings in Bristol-Myers Squibb by 1.9% during the first quarter. Fisher Asset Management LLC now owns 666,264 shares of the biopharmaceutical company’s stock worth $36,231,000 after purchasing an additional 12,534 shares in the last quarter. BTR Capital Management Inc. raised its holdings in Bristol-Myers Squibb by 19.5% during the first quarter. BTR Capital Management Inc. now owns 4,603 shares of the biopharmaceutical company’s stock worth $250,000 after purchasing an additional 750 shares in the last quarter. Finally, Profund Advisors LLC raised its holdings in Bristol-Myers Squibb by 7.3% during the first quarter. Profund Advisors LLC now owns 101,905 shares of the biopharmaceutical company’s stock worth $5,542,000 after purchasing an additional 6,928 shares in the last quarter. 68.88% of the stock is currently owned by hedge funds and other institutional investors.
BMY has been the topic of a number of research analyst reports. Hilliard Lyons cut shares of Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 price objective on the stock. in a report on Tuesday, September 12th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and set a $65.00 price objective (up previously from $62.00) on shares of Bristol-Myers Squibb in a report on Thursday, September 7th. Jefferies Group LLC raised their price objective on shares of Bristol-Myers Squibb from $66.00 to $72.00 and gave the stock a “buy” rating in a report on Monday, September 11th. Piper Jaffray Companies set a $60.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Thursday, July 27th. Finally, BMO Capital Markets reissued a “sell” rating and set a $49.00 price objective on shares of Bristol-Myers Squibb in a report on Monday, September 4th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have given a buy rating to the company. Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $61.84.
In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the sale, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at $2,777,820. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Theodore R. Samuels II bought 6,000 shares of the company’s stock in a transaction on Wednesday, August 2nd. The stock was bought at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the transaction, the director now directly owns 18,000 shares of the company’s stock, valued at $1,006,920. The disclosure for this purchase can be found here. 0.23% of the stock is owned by company insiders.
Bristol-Myers Squibb Company (BMY) opened at 63.80 on Friday. The company has a 50-day moving average of $61.33 and a 200-day moving average of $56.59. The stock has a market capitalization of $104.63 billion, a price-to-earnings ratio of 23.30 and a beta of 1.19. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $64.79. Bristol-Myers Squibb also was the recipient of unusually large options trading on Wednesday. Stock investors acquired 37,577 call options on the stock. This is an increase of 274% compared to the average volume of 10,041 call options.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The firm had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. During the same period last year, the company earned $0.69 earnings per share. The firm’s revenue for the quarter was up 5.6% on a year-over-year basis. Equities research analysts expect that Bristol-Myers Squibb Company will post $2.98 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be given a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 2.45%. The ex-dividend date of this dividend is Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio is presently 56.73%.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.